

---

**RESULTS OF THE TWENTY-FIFTH ANNUAL GENERAL MEETING HELD ON NOVEMBER 28, 2023**

---

The Board of Directors of Vicplas International Ltd (the “**Company**”) is pleased to announce, that at the Twenty-Fifth Annual General Meeting (the “**AGM**”) of the Company held today, all resolutions as set out in the Notice of the AGM dated November 6, 2023, were put to vote by poll and were duly passed at the AGM held today.

(a) Slide Presentations

Before the meeting proceeded with the business of the AGM, the Corporate presentation was presented to the shareholders and copies of these are attached hereto.

(b) Breakdown of all valid votes cast at the AGM

The information as required under Rule 704(16)(a) of the Listing Manual of the Singapore Exchange Securities Trading limited (“**SGX-ST**”) is set out below:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<b>Ordinary Business</b>					
<b>Ordinary Resolution 1</b> To receive and adopt the Directors’ Statement and the Audited Financial Statements of the Company for the year ended July 31, 2023 and the Auditor’s Report thereon.	353,005,227	353,004,227	100	1,000	0
<b>Ordinary Resolution 2</b> To declare a final (one-tier tax exempt) dividend of S\$0.0045 per share for the year ended July 31, 2023.	353,005,227	353,004,227	100	1,000	0

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<b>Ordinary Resolution 3</b> To approve the Directors' fees of S\$272,712.00 for the year ended July 31, 2023.	352,998,690	352,997,690	100	1,000	0
<b>Ordinary Resolution 4</b> To re-elect Mr. Yeo Wico as a Director pursuant to Article 115 of the Company's Constitution.	341,726,952	341,725,952	100	1,000	0
<b>Ordinary Resolution 5</b> To re-elect Mr. Ng Cher Yan as a Director pursuant to Article 115 of the Company's Constitution.	349,781,300	349,780,300	100	1,000	0
<b>Ordinary Resolution 6</b> To re-appoint Deloitte & Touche LLP as Auditor and to authorise the Directors to fix its remuneration.	353,005,227	353,004,227	100	1,000	0
<b>Special Business</b>					
<b>Ordinary Resolution 7</b> To authorise the Directors to issue additional shares and convertible instruments.	353,000,427	352,789,927	99.94	210,500	0.06
<b>Ordinary Resolution 8</b> To approve the renewal of the Interested Person Transactions Mandate.	48,298,586	48,297,586	100	1,000	0
<b>Ordinary Resolution 9</b> To approve the renewal of the Share Purchase Mandate.	353,005,227	353,004,227	100	1,000	0

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<b>Ordinary Resolution 10</b> To authorise the grant of options and the allotment and issuance of shares pursuant to the Vicplas International Share Option Plan 2021.	298,087,902	297,952,402	99.95	135,500	0.05
<b>Ordinary Resolution 11</b> To authorise the issuance of shares pursuant to the Vicplas International Ltd Scrip Dividend Scheme.	353,005,227	352,979,227	99.99	26,000	0.01

(c) Details of parties who are required to abstain from voting on any resolutions

Pursuant to Rule 704(16)(b) of the Listing Manual of the SGX-ST, the details of parties who are required to abstain from voting on the resolutions tabled at the AGM are set out below.

Resolution Number and Details	Name	Total Number of Shares
<b>Ordinary Resolution 8</b> To approve the renewal of the Interested Person Transactions Mandate.	Venner Capital S.A., its subsidiaries and associates, being interested persons (as described in paragraph 4.1 of the Appendix to the Circular to shareholders dated November 6, 2023 (the “Circular”))	280,852,441
	Mrs. Jane Rose Philomene Gaines-Cooper (as described in paragraph 2.5 of the Circular)	23,854,200
<b>Ordinary Resolution 10</b> To authorise the grant of options and the allotment and issuance of shares pursuant to the Vicplas International Share Option Plan 2021.	Directors of the Company who are eligible to participate in the VISOP 2021 and who are also shareholders:	
	Mr. Yeo Wico	11,271,738
	Mr. Ng Cher Yan	3,217,390
	Mr. Ng Beng Tiong	400,000

	Mrs. Jane Rose Philomene Gaines-Cooper	23,854,200
	Employees of the Company/its subsidiaries who are eligible to participate in the VISOP 2021 and who are also shareholders	16,573,997

The Chairman of the AGM only accepted appointment as proxy with respect to the Ordinary Resolutions in the above table for shareholders who were not required to abstain from voting their shares on the relevant Ordinary Resolution(s) and where such shareholder had given specific instructions in a validly completed and submitted instrument of proxy as to voting, or abstentions from voting, in respect of the relevant Ordinary Resolution(s).

(d) Name of firm appointed as scrutineer

CACS Corporate Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

(e) Re-election of Directors

Mr. Yeo Wico, who was re-elected as a Director of the Company at the AGM, will remain as an Independent and Non-Executive Director, the Chairman of the Board, the Chairman of each of the Nominating Committee (“**NC**”) and the Strategy Committee, and a member of each of the Audit and Risk Committee (“**ARC**”) and the Remuneration Committee (“**RC**”) of the Company. Mr. Yeo Wico is considered by the Board to be independent for purposes of Rule 704(8) of the Listing Manual of the SGX-ST.

Mr. Ng Cher Yan, who was re-elected as a Director of the Company at the AGM, will remain as an Independent and Non-Executive Director, the Chairman of each of the ARC and RC and a member of the NC of the Company. Mr. Ng Cher Yan is considered by the Board to be independent for purposes of Rule 704(8) of the Listing Manual of the SGX-ST.


BY ORDER OF THE BOARD

Walter Tarca  
Group Chief Executive Officer  
November 28, 2023



# VICPLAS INTERNATIONAL LTD

**Welcome to the 2023  
Annual General Meeting**




---

# Company Overview

VICPLAS INTERNATIONAL LTD



# Company Presence



## Business Segments

### Medical devices segment

**Forefront Medical** designs, develops and manufactures sterile and non-sterile medical devices

### Pipes & pipe fittings segment

**Vicplas Holdings ("Vicplas Pipes")** manufactures and distributes piping systems for diverse industries

Total employees : 950 + worldwide


## Accreditations

The subsidiaries in the pipes and pipe fittings segment have ISO9001:2015 quality certifications. Vicplas Holdings Pte Ltd additionally is ISO50001:2018, ISO14001:2015 and ISO45001:2018 certified. The subsidiaries in the medical devices segment have EN ISO13485:2016 quality certifications and with the exception of XentiQ (Pte.) Ltd., are registered under the United States Food and Drug Administration (FDA) as a "contract manufacturer for medical devices" and Accreditation certificate of foreign medical device manufacturer from Japan Ministry of Health, Labour and Welfare. Forefront Medical Investments Pte. Ltd. additionally has a Class A, B, C, D Medical Device manufacturer license registered under Health Science Authority (HAS) Singapore and is ISO14001:2015, ISO45001:2018 and ISO50001:2018 certified. Forefront Medical Technology (Jiangsu) Co., Ltd additionally has a Class II Medical Device Manufacturing License in China.

---

# Financial Information

VICPLAS INTERNATIONAL LTD





# Financial Overview

- FY2023 Group revenue dipped 1.2% and net profit after tax fell by 52.1% compared to FY2022, while Adjusted EBITDA fell by 19.9% to S\$14.7M compared to FY2022.
- Net profit margin decreased by 3.5 percentage points to 3.3%
- Medical devices segment had a slight revenue fall of 2.2% due to some customers reducing orders as inventory rebalancing continues post pandemic
- Pipes and pipe fitting segment's revenue grew by 1.2% in FY2023 and segmental results rose 59.9% as compared to FY2022 as construction activities in Singapore improved

## Group

S\$'000	FY2023	FY2022	% Change
<b>Revenue</b>	<b>129,216</b>	130,808	-1.2
<b>Net Profit before Tax</b>	<b>5,609</b>	11,006	-49.0
<b>Net Profit after Tax</b>	<b>4,238</b>	8,839	-52.1
<b>Net Profit Margin</b>	<b>3.3%</b>	6.8%	-3.5 pts
<b>Adjusted EBITDA<sup>1</sup></b>	<b>14,662</b>	18,299	-19.9

## Segment

S\$'000		FY2023	FY2022	% Change
<b>Medical Devices</b>	<b>Revenue</b>	<b>90,558</b>	92,601	-2.2
	<b>Segmental Result<sup>2</sup></b>	<b>3,401</b>	10,229	-66.8
<b>Pipes &amp; Pipe Fittings</b>	<b>Revenue</b>	<b>38,658</b>	38,207	1.2
	<b>Segmental Result<sup>2</sup></b>	<b>7,199</b>	4,503	59.9


<sup>1</sup> Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortisation; and excludes unrealised foreign exchange by adding back unrealised foreign exchange loss and deducting unrealised foreign exchange gain.

<sup>2</sup> The segmental result of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.

# Revenue

- Over the past six financial years, the Group achieved revenue growth with a CAGR of 10.9%
- Forefront Medical's contribution to overall revenue is approximately 70% as the Group transforms into a medical device-focused group
- Vicplas Pipes, an industry leader in the supply of pipes and pipe fittings, saw an improved performance as the construction activities in Singapore improved
- Manufacturing presence in Singapore and wide range of quality products certified with 4 Green Marks from the Singapore Green Building Council allows it to better support customers as the domestic construction industry continues its growth momentum
- Vicplas Pipes will help support the Group's performance as Forefront Medical further develops its capabilities and grows its market share in the growing MedTech contract development and manufacturing industry

S\$ million




# Profit

FY2023 profit performance compared to FY2022 was impacted by:

- 24.7% decrease in other income mainly due to the decrease in income from tooling, mould and maintenance services as compared to FY2022
- 1.2% decrease in raw material and consumables used due to the decrease in production activities
- 3.0% decrease in employee salary and benefits expense due to decreased headcount and overtime, especially in the medical devices segment
- 16.5% increase in other operating expenses mainly due to costs incurred in the first full year of operations at the new Changzhou plant extension, costs related to the establishment of the planned new plant in Mexico, higher marketing and travelling costs as the Group sourced for new business opportunities as markets reopened post pandemic, and higher foreign exchange loss
- 35.0% increase in finance costs due to the higher interest rate environment

S\$ million




# NAV Per Share

- The Group's net asset value (NAV) per share has steadily increased year-on-year since FY2018, including during the pandemic, at a CAGR of 5.7%
- This highlights the Group's strong and resilient fundamentals, as our growing medical device segment gains traction while our pipes and pipe fittings segment provides a stable base



# Segmental Result – Forefront Medical

- In FY2023, Forefront Medical's revenue fell by 2.2% to S\$90.2m as certain customers adjusted their inventory levels post pandemic, and the softer ordering situation is expected to continue until this rightsizing exercise has been completed
- The segment also incurred higher operating costs mainly due to the effects of rising supply chain costs and other disruptions caused by the pandemic
- Lastly, an increase in investments in technical resources, the new Changzhou plant extension, unrealised foreign exchange loss, plus higher sales and marketing activities, also affected the segmental results




\*The segmental result of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.

# Segmental Result - Vicplas Pipes

S\$ million

- Vicplas Pipes' FY2023 revenue increased to S\$38.7m as Singapore's construction industry improved
- Segmental results saw a 59.9% increase to S\$7.2m due to a combination of lower material costs, extensive cost containment and efficiency improvement measures in the manufacturing plants



\*The segmental result of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.

# Forefront Medical Devices

Presented by


**Walter Tarca**

Group CEO





# POSITIONED FOR LONG TERM GROWTH





# Our Vision

To be a leading global medical device manufacturing partner with solutions that are preferred by product owners

- 100% focused on manufacturing quality devices for the medical device industry
- Global customer base in five continents
- More than 800 employees
- Committed to providing our customers and their patients with innovative and cost-effective medical devices to enable continuous improvements in healthcare



# About Us

Forefront Medical is a medical device specialist in the contract development and manufacturing industry(CDMO), offering industrial and product designs with strong specialisation in the electro-mechanical , injection and blow molding and extrusion fields together with an extended range of services and support to add value to our customers throughout the world and their patients.



# Global Presence



Singapore – Corporate HQ



Changzhou, China



Xiamen, China



Plant Extension in Changzhou, China



Juarez, Mexico

## Manufacturing Sites

- Singapore – Corporate HQ (7,410m<sup>2</sup>)
- Xiamen, China (7,000m<sup>2</sup>)
- Changzhou, China (7,024m<sup>2</sup> + 7,000m<sup>2</sup> extension)
- Kington, UK (2,600m<sup>2</sup>)
- Juarez, Mexico (7000M2) from 3<sup>rd</sup> Calander Qtr 2024)

## Commercial Offices

- Singapore
- Shanghai, China
- Connecticut, USA
- Kington, UK

# Extensive In-House Capabilities: From Concept to Manufacturing



PediGuard for Spinal Surgery



Feeding PVC Tube with Tungsten



Laryngeal Mask with LSR Cuff



Reinforced Extruded Silicone Tube


Design & Development	<ul style="list-style-type: none"> <li>Product Concept &amp; Realisation</li> <li>Electronics, Software, Metal Parts</li> </ul>	
Rapid Prototyping		
Plastic & LSR Tooling	<ul style="list-style-type: none"> <li>In-house Toolroom &amp; Design Team</li> <li>Insert Mould</li> </ul>	<ul style="list-style-type: none"> <li>Micro Mould</li> <li>2K Mould</li> <li>Stack Mould</li> </ul>
Moulding Capabilities	<ul style="list-style-type: none"> <li>Wide Range of Materials</li> <li>Injection</li> <li>Extrusion</li> </ul>	<ul style="list-style-type: none"> <li>Injection Blow</li> <li>Extrusion Blow</li> </ul>
Production	<ul style="list-style-type: none"> <li>Cleanroom Facility</li> <li>Pilot/Trial Run</li> </ul>	<ul style="list-style-type: none"> <li>Low Mix High Volume</li> <li>High Mix Low Volume</li> </ul>
Quality	<ul style="list-style-type: none"> <li>ISO 13485</li> <li>FDA 510K</li> </ul>	<ul style="list-style-type: none"> <li>CE Mark</li> <li>IQ/OQ/PQ</li> </ul>
Assembly	<ul style="list-style-type: none"> <li>Manual Assembly</li> <li>High Speed Automation</li> </ul>	
Secondary Processes	<ul style="list-style-type: none"> <li>Hydrophilic Coating</li> <li>RF Tipping &amp; Forming</li> </ul>	<ul style="list-style-type: none"> <li>Pad Printing</li> <li>Bonding &amp; Welding</li> </ul>
Packing	<ul style="list-style-type: none"> <li>Rigid Blister</li> <li>Soft Blister</li> </ul>	<ul style="list-style-type: none"> <li>Tyvek Pouch</li> <li>Pallet Optimisation</li> </ul>
Sterillization	<ul style="list-style-type: none"> <li>EtO</li> <li>Gamma</li> </ul>	<ul style="list-style-type: none"> <li>Autoclave</li> <li>E-Beam</li> </ul>

# Our Medical Device Portfolio


- Vascular
- Pharmaceutical Bottles
- Surgical Devices
- Respiratory
- Orthodontics
- Patient monitoring devices
- Airway Management
- Cell & Gene Therapy
- Endoscopy
- Drug Delivery systems
- Diagnostics
- Enteral feeding

## Bringing Medical Innovations to Life

Over 92% of our products are for one time only use and are fully completed products



# R&D – DESIGN ENHANCEMENT (XENTIQ)



**Clearblue** - Digital Pregnancy Test with Conception Indicator

# ENGINEERING & DESIGN (XENTIQ)



**Product Concepts**

Product Commercialization Strategy

Feasibility Studies

Conceptual Design  
Detail Design



**Product Realization**

Engineering, Mechanical, Electronics, Software

Regulatory Approvals

Design for Manufacturing



**Experimental Prototypes**

Proof of concept

Prototyping for Animal Models, Cadaver and Animal Studies

Usability (Physical)



**Product Segments**

Passive Consumables

Active Devices

Surgical tools, diagnostic, physical therapy



**Industry Collaborations**

Clinicians

Researchers

Institutes of higher learning



**Histoindex Genesis – Imaging System**



**Pedi Guard for Spine Guard- Safer Spine Surgery**

# INJECTION MOLDED MEDICAL COMPONENTS



- **Micro-Molding**
- **Insert Molding**  
(plastics & metals)
- **Co-Injection**
- **Multi-Shot Molding**
- **Unscrew Molding**
- **Tooling Capabilities**  
Stack Mold  
Spin-Stack Mold  
In-Mold Assembly



# EXTRUSION MEDICAL TUBINGS

- **Single / Multi-lumen tubes**
- **Braided tubes**
- **Co Extrusion**
- **Multi Color/Layer Extrusion**
- **Small bore tubes** (catheters)
- **Spiral / Corrugated Tubes**
- **Specialty Tubes** (Radio Opaque Additives added tube)



## Material

- **PVC**
- **Nylon / Pebex**
- **FEP / PTFE**
- **Silicone**

# BLOW MOLDING OF MEDICAL BOTTLES

Nasal Spray Bottle

Product Development | Injection | Extrusion | Blow Molding | Assembly | Packaging | Sterilization



# FULL DEVICE – HIGH PRESSURE INFLATION DEVICE

Injection | Assembly | Packaging | Sterilization

## Secondary Processes Involved

- **Assembly**
- **Pad Printing**
- **Adhesive/Solvent Bonding**
- **UV Curing**
- **Tray sealing & Packaging**





## FULL DEVICE - INFUSION SET

Injection | Extrusion | Assembly | Packaging | Sterilization

# FULL DEVICE - LARYNGEAL MASK

Injection | Extrusion | Blow | Assembly | Packaging | Sterilization

## Laryngeal Mask

a medical device that keeps a patient's airway open during anaesthesia or unconsciousness



### Secondary Processes

- **Assembly**
- **Shape Forming**
- **Pad Printing**
- **Adhesive/Solvent Bonding**
- **UV Curing**
- **Form, Fill & Seal**

# FULL DEVICE - JEJUNAL & NASO GASTRIC FEEDING TUBE

## Secondary Processes

- **Assembly**
- **Hydrophilic Coating**
- **Adhesive/Solvent Bonding**
- **UV Curing**
- **Tyvek Pouch Packaging**

Injection | Extrusion | Blow | Assembly | Packaging | Sterilization

**Jejunal Gastric Decompression Tube**  
*Designed for easy insertion through Bard Percutaneous Endoscopic Gastrostomy (PEG) Tube*

# TEXTILE MANUFACTURING



# FOREFRONT IN THE AI + ORTHODONTICS SPACE !



## FULL DEVICE – SCANBOX

Injection | Assembly | Packaging






# Opportunities in Medtech Industry

The global medical devices market is projected to grow from \$536.12 billion in 2023 to \$799.67 billion by 2030 at a CAGR of 5.9% during the forecast period.\*

## Key drivers:

- Growing prevalence of chronic diseases and increasing emphasis of healthcare agencies toward early diagnosis and treatment
- Rise in number of inpatient admissions and increasing number of surgical and diagnostic procedures
- Rising investments from leading healthcare market players and medtech companies for R&D and favourable scenarios provided by regulatory authorities

Global Medical Devices Market Size  
(in USD Billions)




# Contract Development & Manufacturing Market is Growing

The MedTech contract development and manufacturing organisation (CDMO) market is expected to grow by an average of 11.4% year-on-year through 2025.

## Key drivers:

- Ageing population
- Increased demand for improved healthcare in developing markets
- Continued willingness by product owners to outsource manufacturing to trusted partners that can fully support product and process innovation in the right geographical locations

MedTech CDMO Market by Application: 2019-2025e (US\$B)




<https://www.meddeviceonline.com/doc/pocket-guide-to-medtech-market-outlook-in-0001>  
<https://www.meddeviceonline.com/doc/trends-in-medical-device-contract-manufacturing-what-medtech-oems-need-to-know-0001>



# FY2023 HIGHLIGHTS


- FY2023 results were negatively impacted by softening demand in the medical devices segment as some customers clear excess stock built up during the uncertainty of the pandemic. There is a temporary reduction in new orders, as inventory levels are rebalanced.
- There were also increased operating expenses such as the new Changzhou plant extension costs, costs related to the establishment of the planned new plant in Mexico as well as higher marketing and travelling costs to source for new business opportunities as markets reopened post pandemic
- Development of an additional near shore USA manufacturing site in Mexico is proceeding as planned, which when complete will improve the segment's ability to collaborate and offer additional services to its global customer base
- Segment continues to prioritise building of new capabilities and efficiency improvements
- Continued to commercialise customer projects including specific market projects for China

# SUSTAINABLE LONG TERM SALES GROWTH



# Achieving Our Vision: Strategic Intent

To improve profitability by  
delivering great solutions for our  
customers and building  
sustainable value for all our  
stakeholders



# Strategic Priorities



## Accelerate Capital Investments

- Broaden global footprint to satisfy demand and improve flexibility of supply chains for new and existing customers
  - Changzhou extension completed & utilisation improving
  - Juarez, Mexico plant planning progressing well



## Drive Capability Improvements & Innovation

- Prioritise efficiency improvements and cost reductions at all manufacturing locations
- Build expanded capabilities in medical extrusions, cell and gene therapy and electro-mechanical devices to strengthen new revenue streams
- Continued investment in collaborative projects with MedTech product owners to expand our capabilities and drive growth




## Build A High Performance Team To Drive Growth

- Continue to develop and provide opportunities for our highly engaged, tenured team
- Invest in additional MedTech talent pool to drive new revenue streams and manage growth

# Business Outlook

- Segmental revenue is expected to remain constrained as customer inventory adjustment continues
- Segmental result may also be impacted by rising operating costs due to inflationary pressures and higher development and expansion costs
- Long term prospects remain bright as the segment continues to improve its operating efficiencies, implement cost reductions, invest in new capabilities and develop the new Mexico plant to expand its manufacturing footprint in the Americas
- Cautious about challenges that may arise from uncertainties in the global macroeconomic environment, plus ongoing inflationary and interest rate pressures
- Will continue to exercise prudent cost controls, while developing new business opportunities, and positioning its base for future growth



# Vicplas Pipes & Pipe Fittings


Presented by

**Jay Cheng**

Group Operations  
Director









# A SUSTAINABLE BUSINESS




# About Us

Vicplas Pipes is a leading solutions provider in the plastic pipe manufacturing industry. Our uPVC piping systems are found in a majority of residential homes across Singapore. Our market leadership is built on the quality and reliability of our products. They are commonly found in:

- **Plumbing and Electrical Works** across residential, commercial, institutional, industrial and other buildings
- **Civil Engineering Works** ranging from telecommunication and power grid pipelines to infrastructure works






# Delivering Green and Innovative solutions beyond the built environment

Driving us forward

# Industry Leader in the built environment



- SGBP Green Mark Scheme – 4<sup>th</sup> Green Marks accrue the maximum point rating for products used towards the project's Green Mark Rating.
- 4<sup>th</sup> Green Marks achieved – Vicplas is now the recognised industry leader for waste and potable water piping systems.
- Also the 1<sup>st</sup> uPVC pipes and pipe fittings producer in Singapore to be Green Mark certified.
- 4<sup>th</sup> Green Marks creates new opportunities for Vicplas pipes to expand beyond Singapore as the built environment regionally adopts green certified products more widely.



# Core Capabilities



## Product Design

Develop practical, cost-efficient solutions that evolve with the changing needs of customers



## Processing Techniques

Proficient across a range of polymer processing techniques and able to offer injection, extrusion, thermal forming and fabrications



## Tool Fabrication

Equipped with in-house mould design and fabrication capabilities



## Materials Know-how

Extensive working knowledge of polymeric materials such as engineering plastics, specialty elastomers, composites and more



# Value Proposition To Customers

## **Solutions Provider**

Proactively look for new product development opportunities to fill industry gaps and meet emerging needs



## **Product Reliability**

Conduct regular quality checks to ensure that products meet stringent quality and regulatory requirements

## **Research & Development**

Constantly explore new possibilities in the design and manufacture of our products

## **Operational Efficiency**

Invest in new technologies and improve existing process to enhance operational and manufacturing efficiency

## **Green Initiatives**

Contribute to a cleaner and greener future by developing environmentally friendly products

# Application



## Buildings

- Residential homes
- Commercial/ Institutional buildings
- Industrial and others



## Hydro-agriculture

- Irrigation pipelines
- Grow Channels



## Civil Engineering

- Telecommunication pipelines
- Power gride pipelines
- Infrastructure works



## FY2023 HIGHLIGHTS

- Segmental revenue in FY2023 increased by 1.2% to S\$38.7 million from the same period last year as construction activity in Singapore improves
- FY2023 segmental result saw a 59.9% increase to S\$7.2 million from the same period last year due to lower material costs, extensive cost containment and efficiency improvement measures in the manufacturing plants



# Business Outlook

- Well-positioned to meet the increase in demand from public housing to be launched over the next few years
- Segment will continue to focus on civil engineering projects and product expansion
- Challenges in the current operating environment such as intensified competition, cost pressures and credit risk exposures likely to continue





# Thank You

[www.vicplas.com.sg](http://www.vicplas.com.sg)  
35 Joo Koon Circle  
Singapore 629110  
+65 62623888